Global Multi-target MET TKIs Market Growth 2024-2030

Publication ID:

LPI11242606

Publication Date:

November 19, 2024

Pages:

109

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Multi-target MET tyrosine kinase inhibitors (TKIs) are a class of drugs ,designed to inhibit the MET receptor tyrosine kinase and other related or unrelated tyrosine kinases to block multiple signaling pathways involved in cancer progression.
The global Multi-target MET TKIs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淢ulti-target MET TKIs Industry Forecast鈥� looks at past sales and reviews total world Multi-target MET TKIs sales in 2023, providing a comprehensive analysis by region and market sector of projected Multi-target MET TKIs sales for 2024 through 2030. With Multi-target MET TKIs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Multi-target MET TKIs industry.
This Insight Report provides a comprehensive analysis of the global Multi-target MET TKIs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Multi-target MET TKIs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Multi-target MET TKIs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Multi-target MET TKIs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Multi-target MET TKIs.
United States market for Multi-target MET TKIs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Multi-target MET TKIs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Multi-target MET TKIs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Multi-target MET TKIs players cover Pfizer, Exelixis, MSN Labs, Stada Arzneimittel, Teva, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Multi-target MET TKIs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
cabozantinib
Crizotinib
Other
Segmentation by Application:
Non-small Cell Lung Cancer
Medullary Thyroid Cancer
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Pfizer
Exelixis
MSN Labs
Stada Arzneimittel
Teva
Cipla
BDR Pharma
Elemento Pharma
Beacon Pharmaceuticals
Wanbang Biopharmaceuticals
Drug International
Genvio Pharma
Everest Pharmaceuticals
Zydus
Key Questions Addressed in this Report
What is the 10-year outlook for the global Multi-target MET TKIs market?
What factors are driving Multi-target MET TKIs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Multi-target MET TKIs market opportunities vary by end market size?
How does Multi-target MET TKIs break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Multi-target MET TKIs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Multi-target MET TKIs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Multi-target MET TKIs by Country/Region, 2019, 2023 & 2030
2.2 Multi-target MET TKIs Segment by Type
2.2.1 cabozantinib
2.2.2 Crizotinib
2.2.3 Other
2.3 Multi-target MET TKIs Sales by Type
2.3.1 Global Multi-target MET TKIs Sales Market Share by Type (2019-2024)
2.3.2 Global Multi-target MET TKIs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Multi-target MET TKIs Sale Price by Type (2019-2024)
2.4 Multi-target MET TKIs Segment by Application
2.4.1 Non-small Cell Lung Cancer
2.4.2 Medullary Thyroid Cancer
2.4.3 Other
2.5 Multi-target MET TKIs Sales by Application
2.5.1 Global Multi-target MET TKIs Sale Market Share by Application (2019-2024)
2.5.2 Global Multi-target MET TKIs Revenue and Market Share by Application (2019-2024)
2.5.3 Global Multi-target MET TKIs Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Multi-target MET TKIs Breakdown Data by Company
3.1.1 Global Multi-target MET TKIs Annual Sales by Company (2019-2024)
3.1.2 Global Multi-target MET TKIs Sales Market Share by Company (2019-2024)
3.2 Global Multi-target MET TKIs Annual Revenue by Company (2019-2024)
3.2.1 Global Multi-target MET TKIs Revenue by Company (2019-2024)
3.2.2 Global Multi-target MET TKIs Revenue Market Share by Company (2019-2024)
3.3 Global Multi-target MET TKIs Sale Price by Company
3.4 Key Manufacturers Multi-target MET TKIs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Multi-target MET TKIs Product Location Distribution
3.4.2 Players Multi-target MET TKIs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Multi-target MET TKIs by Geographic Region
4.1 World Historic Multi-target MET TKIs Market Size by Geographic Region (2019-2024)
4.1.1 Global Multi-target MET TKIs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Multi-target MET TKIs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Multi-target MET TKIs Market Size by Country/Region (2019-2024)
4.2.1 Global Multi-target MET TKIs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Multi-target MET TKIs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Multi-target MET TKIs Sales Growth
4.4 APAC Multi-target MET TKIs Sales Growth
4.5 Europe Multi-target MET TKIs Sales Growth
4.6 Middle East & Africa Multi-target MET TKIs Sales Growth
5 Americas
5.1 Americas Multi-target MET TKIs Sales by Country
5.1.1 Americas Multi-target MET TKIs Sales by Country (2019-2024)
5.1.2 Americas Multi-target MET TKIs Revenue by Country (2019-2024)
5.2 Americas Multi-target MET TKIs Sales by Type (2019-2024)
5.3 Americas Multi-target MET TKIs Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Multi-target MET TKIs Sales by Region
6.1.1 APAC Multi-target MET TKIs Sales by Region (2019-2024)
6.1.2 APAC Multi-target MET TKIs Revenue by Region (2019-2024)
6.2 APAC Multi-target MET TKIs Sales by Type (2019-2024)
6.3 APAC Multi-target MET TKIs Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Multi-target MET TKIs by Country
7.1.1 Europe Multi-target MET TKIs Sales by Country (2019-2024)
7.1.2 Europe Multi-target MET TKIs Revenue by Country (2019-2024)
7.2 Europe Multi-target MET TKIs Sales by Type (2019-2024)
7.3 Europe Multi-target MET TKIs Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Multi-target MET TKIs by Country
8.1.1 Middle East & Africa Multi-target MET TKIs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Multi-target MET TKIs Revenue by Country (2019-2024)
8.2 Middle East & Africa Multi-target MET TKIs Sales by Type (2019-2024)
8.3 Middle East & Africa Multi-target MET TKIs Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Multi-target MET TKIs
10.3 Manufacturing Process Analysis of Multi-target MET TKIs
10.4 Industry Chain Structure of Multi-target MET TKIs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Multi-target MET TKIs Distributors
11.3 Multi-target MET TKIs Customer
12 World Forecast Review for Multi-target MET TKIs by Geographic Region
12.1 Global Multi-target MET TKIs Market Size Forecast by Region
12.1.1 Global Multi-target MET TKIs Forecast by Region (2025-2030)
12.1.2 Global Multi-target MET TKIs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Multi-target MET TKIs Forecast by Type (2025-2030)
12.7 Global Multi-target MET TKIs Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Multi-target MET TKIs Product Portfolios and Specifications
13.1.3 Pfizer Multi-target MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Exelixis
13.2.1 Exelixis Company Information
13.2.2 Exelixis Multi-target MET TKIs Product Portfolios and Specifications
13.2.3 Exelixis Multi-target MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Exelixis Main Business Overview
13.2.5 Exelixis Latest Developments
13.3 MSN Labs
13.3.1 MSN Labs Company Information
13.3.2 MSN Labs Multi-target MET TKIs Product Portfolios and Specifications
13.3.3 MSN Labs Multi-target MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 MSN Labs Main Business Overview
13.3.5 MSN Labs Latest Developments
13.4 Stada Arzneimittel
13.4.1 Stada Arzneimittel Company Information
13.4.2 Stada Arzneimittel Multi-target MET TKIs Product Portfolios and Specifications
13.4.3 Stada Arzneimittel Multi-target MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Stada Arzneimittel Main Business Overview
13.4.5 Stada Arzneimittel Latest Developments
13.5 Teva
13.5.1 Teva Company Information
13.5.2 Teva Multi-target MET TKIs Product Portfolios and Specifications
13.5.3 Teva Multi-target MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Teva Main Business Overview
13.5.5 Teva Latest Developments
13.6 Cipla
13.6.1 Cipla Company Information
13.6.2 Cipla Multi-target MET TKIs Product Portfolios and Specifications
13.6.3 Cipla Multi-target MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Cipla Main Business Overview
13.6.5 Cipla Latest Developments
13.7 BDR Pharma
13.7.1 BDR Pharma Company Information
13.7.2 BDR Pharma Multi-target MET TKIs Product Portfolios and Specifications
13.7.3 BDR Pharma Multi-target MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 BDR Pharma Main Business Overview
13.7.5 BDR Pharma Latest Developments
13.8 Elemento Pharma
13.8.1 Elemento Pharma Company Information
13.8.2 Elemento Pharma Multi-target MET TKIs Product Portfolios and Specifications
13.8.3 Elemento Pharma Multi-target MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Elemento Pharma Main Business Overview
13.8.5 Elemento Pharma Latest Developments
13.9 Beacon Pharmaceuticals
13.9.1 Beacon Pharmaceuticals Company Information
13.9.2 Beacon Pharmaceuticals Multi-target MET TKIs Product Portfolios and Specifications
13.9.3 Beacon Pharmaceuticals Multi-target MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Beacon Pharmaceuticals Main Business Overview
13.9.5 Beacon Pharmaceuticals Latest Developments
13.10 Wanbang Biopharmaceuticals
13.10.1 Wanbang Biopharmaceuticals Company Information
13.10.2 Wanbang Biopharmaceuticals Multi-target MET TKIs Product Portfolios and Specifications
13.10.3 Wanbang Biopharmaceuticals Multi-target MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Wanbang Biopharmaceuticals Main Business Overview
13.10.5 Wanbang Biopharmaceuticals Latest Developments
13.11 Drug International
13.11.1 Drug International Company Information
13.11.2 Drug International Multi-target MET TKIs Product Portfolios and Specifications
13.11.3 Drug International Multi-target MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Drug International Main Business Overview
13.11.5 Drug International Latest Developments
13.12 Genvio Pharma
13.12.1 Genvio Pharma Company Information
13.12.2 Genvio Pharma Multi-target MET TKIs Product Portfolios and Specifications
13.12.3 Genvio Pharma Multi-target MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Genvio Pharma Main Business Overview
13.12.5 Genvio Pharma Latest Developments
13.13 Everest Pharmaceuticals
13.13.1 Everest Pharmaceuticals Company Information
13.13.2 Everest Pharmaceuticals Multi-target MET TKIs Product Portfolios and Specifications
13.13.3 Everest Pharmaceuticals Multi-target MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Everest Pharmaceuticals Main Business Overview
13.13.5 Everest Pharmaceuticals Latest Developments
13.14 Zydus
13.14.1 Zydus Company Information
13.14.2 Zydus Multi-target MET TKIs Product Portfolios and Specifications
13.14.3 Zydus Multi-target MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Zydus Main Business Overview
13.14.5 Zydus Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂